Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective

Table 3

Estimation of excess NSHEs attributable to SU utilization versus SGLT2i after metformin in Canada for 2016.

	Base	Minimum	Maximum
With the assumption of probability of only one episode of NSHE per annum per patient	130,434 events per year	80,680	624,465
Estimated compounded events of NSHE per annum	417,389 events per year	260,868	5,047,762

Base scenario assumptions: average estimates for risk difference, number of patients with DM2 in Canada, pattern of SU utilization in Canada, and probability of NSHEs for SU; have not incorporated underreporting for NSHEs in real-world clinical settings. Minimum scenario assumptions: lower estimated boundaries for risk difference, number of patients with DM2 in Canada, pattern of SU utilization in Canada, and probability of NSHEs for SU; have not incorporated underreporting for NSHEs in real-world clinical settings. Maximum scenario assumptions: upper estimated boundaries for risk difference, number of patients with DM2 in Canada, pattern of SU utilization in Canada, and probability of NSHEs for SU; incorporated underreporting for NSHEs in real-world clinical settings.